Premium
HIV infection in Norwegian haemophiliacs: The prevalence of antibodies against HIV in haemophiliacs treated with lyophilized cryoprecipitate from volunteer donors
Author(s) -
Evensen S. A.,
Ulstrup J.,
Skaug K.,
Frøland S. S.,
Glomstein A.,
Rollag H.
Publication year - 1987
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1987.tb00162.x
Subject(s) - cryoprecipitate , haemophilia , medicine , norwegian , human immunodeficiency virus (hiv) , haemophilia a , antibody , population , immunology , volunteer , blood transfusion , virology , pediatrics , biology , platelet , linguistics , philosophy , environmental health , agronomy
334 of 389 (86%) registered Norwegians with coagulation factor defects were screened for antibodies to the human immunodeficiency virus (HIV) in 1985/1986. 21 persons were confirmed anti‐HIV positive. They were all persons with clinically severe haemophilia A and represent 18.4% of 114 tested persons with severe haemophilia A. 3 patients have developed AIDS, 3 have persistent generalized lymphadenopathy. At least 8 of the 21 seropositive persons (38%) have been infected through lyophilized cryoprecipitates prepared from volunteer plasma donated in national blood banks. None of 10 heterosexual partners have antibodies to HIV. We conclude that the policy of using small‐pooled lyophilized cryoprecipitates instead of commercial concentrates has reduced HIV‐infection among Norwegian haemophiliacs. Today, the prevalence of HIV antibodies in the haemophilia population in Norway is among the lowest in Western Europe.